PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jan 06, 2020

byncaipen

Ophthalmology

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to...Read more

Dec 19, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the completion of an in vivo study to assess the effect of AAGP® on the long term survival and...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.